Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin

Blood

Volumn 123, Issue 16, 2014, Pages 2485-2493

  Warkentin, Theodore E ^a   Sheppard, Jo Ann I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FONDAPARINUX; HEPARIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; SEROTONIN;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DEEP VEIN THROMBOSIS; DRUG REEXPOSURE; ENZYME IMMUNOASSAY; FEMALE; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INTRAOPERATIVE PERIOD; MACULOPAPULAR RASH; MALE; MEDICAL HISTORY; MITRAL VALVE REPLACEMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; SEROCONVERSION; SEROLOGY; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; VASCULAR SURGERY;

AGED; CARDIAC SURGICAL PROCEDURES; CHEMOPREVENTION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84899089518     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-533083     Document Type: Article

References (35)

1. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715. (Pubitemid 41510744)
2. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol. 2005;128(6):837-841. (Pubitemid 40444878)
3. Pötschke C, Selleng S, Bröker BM, Greinacher A. Heparin-induced thrombocytopenia: further evidence for a unique immune response. Blood. 2012;120(20):4238-4245.
4. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292. (Pubitemid 32372963)
5. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood. 2009;113(20):4970-4976.
6. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009;113(20):4963- 4969.
7. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71(2):247-251. (Pubitemid 24047336)
8. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93(1):81-88. (Pubitemid 24030823)
9. Gruel Y, Lang M, Darnige L, et al. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet. 1990;336(8722):1077-1078. (Pubitemid 20366399)
10. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008;99(4):779-781. (Pubitemid 351694236)
11. Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343(7):515. (Pubitemid 30646499)
12. Warkentin TE, Sheppard JI, Sun JC, Jung H, Eikelboom JW. Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. J Thromb Haemost. 2013;11(2):253-260.
13. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95(5):1242-1246. (Pubitemid 27097836)
14. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708. (Pubitemid 30661052)
15. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost. 2010;8(1):30-36.
16. Wanaka K, Matsuo T, Matsuo M, et al. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost. 2010;8(3):616-618.
17. Hartman V, Malbrain M, Daelemans R, Meersman P, Zachée P. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract. 2006;104(4):c143-c148. (Pubitemid 44875770)
18. Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T's score. J Thromb Haemost. 2010;8(7):1483-1485.
19. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30. (Pubitemid 16167006)
20. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95(1):161-167. (Pubitemid 26340246)
21. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost. 2011;9(Suppl 1):105-117.
22. Greinacher A, Gopinadhan M, Günther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006;26(10):2386-2393. (Pubitemid 44465738)
23. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost. 2006;4(1):281-282.
24. Althaus K, Strobel U, Warkentin TE, Greinacher A. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res. 2011;128(3):256-260.
25. Warkentin TE, Greinacher A; The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):311S-337S. (Pubitemid 39297959)
26. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):340S-380S. (Pubitemid 351892970)
27. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S.
28. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135(7):502-506. (Pubitemid 32923567)
29. Refaai MA, Warkentin TE, Axelson M, Matevosyan K, Sarode R. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: a consequence of heparin "flushes". Thromb Haemost. 2007;98(5):1139-1140. (Pubitemid 350091145)
30. Alsaleh KA, Al-Nasser SM, Bates SM, Patel A, Warkentin TE, Arnold DM. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol. 2008;83(11):876-878.
31. Warkentin TE, Chakraborty AK, Sheppard JA, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thromb Haemost. 2012;108(2):394-396.
32. Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost. 2011;37(6):653-663.
33. Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370-1378.
34. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood. 2008;112(10):4024-4027.
35. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312. (Pubitemid 352016309)